DelveInsight’s “Alopecia - Pipeline Insight, 2023,” report provides comprehensive insights about 33+ companies and 33+ pipeline drugs in the Alopecia pipeline landscape.
Key Takeaways from the Alopecia Pipeline Report
- Over 33+ companies and 33+ pipeline drugs in Alopecia are in various stages of development, and their anticipated acceptance in the Alopecia market would significantly increase market revenue.
- Leading Alopecia companies developing novel drug candidates to improve the Alopecia treatment landscape include Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.
- Promising Alopecia pipeline therapies in various stages of development include KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 , CTP-543, PF-06651600, and others
Alopecia Overview
Alopecia is the loss of hair in areas anywhere on the body where hair normally grows. Alopecia may be defined as scarring or non-scarring, localized or diffuse, congenital or acquired, reversible or permanent, or confined to the scalp or universal; however, alopecia is usually classified using the 1st 3 factors. The etiologies of alopecia are usually divided into disorders in which the hair follicle is abnormal or damaged and those in which the hair follicle is normal but the cycling of hair growth is abnormal. The most common presentations are androgenetic hair loss, alopecia areata, traction alopecia, tinea capitis, and telogen effluvium. Diagnosis is made through a positive medical history and physical exam findings. Treatment depends on the type and potential for regrowth.
Alopecia Pipeline Analysis: Drug Profile
KX-826: Kintor Pharma
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile.
Baricitinib: Reata Pharmaceuticals
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signaling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signaling molecules and proinflammatory mediators.
Discover more about the emerging Alopecia drugs @ Alopecia Treatment Drugs
Alopecia Pipeline Therapies and Key Companies
- KX-826: Kintor Pharma
- Baricitinib: Reata Pharmaceuticals
And many others
Alopecia Pipeline Therapeutics Assessment
Phases
DelveInsight’s Report covers around 33+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Alopecia Pipeline Report
- Coverage: Global
- Key Alopecia Companies: Intor Pharma, Eli Lilly and Company, Addpharma, TechnoDerma Medicines, Energenesis Biomedical, Pfizer, Biosplice Therapeutics, Inc., Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare SA, Eurofarma Laboratorios S.A., 3SBio, Arena Pharmaceuticals, AnaptysBio, Inc., Reistone Biopharma Company Limited, Biosplice Therapeutics, Inc., LEOPharma, Intrepid Therapeutics and others.
- Key Alopecia Pipeline Therapies: KX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 , CTP-543, PF-06651600 and others.
- Find out more about the Alopecia treatment options in development @ Alopecia Clinical Trials
Table of Contents
1. Alopecia Introduction
2. Alopecia Executive Summary
3. Alopecia Overview
4. Alopecia Pipeline Therapeutics
5. Alopecia Late-Stage Products (Phase III)
6. Alopecia Mid-Stage Products (Phase II)
7. Alopecia Early Stage Products (Phase I/II)
8. Alopecia Preclinical Stage Products
9. Alopecia Discovery Stage Products
10. Alopecia Therapeutic Assessment
11. Alopecia Inactive Products
12. Alopecia Collaborations Assessment- Licensing / Partnering / Funding
13. Alopecia Unmet Needs
14. Alopecia Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
